Detalhe da pesquisa
1.
Searching for the "Holy Grail" of breast cancer recurrence risk: a narrative review of the hunt for a better biomarker and the promise of circulating tumor DNA (ctDNA).
Breast Cancer Res Treat
; 205(2): 211-226, 2024 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-38355821
2.
Interplay between ESR1/PIK3CA codon variants, oncogenic pathway alterations and clinical phenotype in patients with metastatic breast cancer (MBC): comprehensive circulating tumor DNA (ctDNA) analysis.
Breast Cancer Res
; 25(1): 112, 2023 10 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-37784176
3.
Case 15-2021: A 76-Year-Old Woman with Nausea, Diarrhea, and Acute Kidney Failure.
N Engl J Med
; 384(20): 1943-1950, 2021 May 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-34010534
4.
Optimizing Access to Liquid Biopsy in the Present and Future Cancer Landscape.
JCO Precis Oncol
; 8: e2300609, 2024 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-38271658
5.
Novel oral selective estrogen receptor degraders (SERDs) to target hormone receptor positive breast cancer: elacestrant as the poster-child.
Expert Rev Anticancer Ther
; 24(6): 397-405, 2024 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-38642015
6.
Genomic spectrum of actionable alterations in serial cell free DNA (cfDNA) analysis of patients with metastatic breast cancer.
NPJ Breast Cancer
; 10(1): 27, 2024 Apr 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-38605020
7.
CDK4/6 Inhibitor Efficacy in ESR1-Mutant Metastatic Breast Cancer.
NEJM Evid
; 3(5): EVIDoa2300231, 2024 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-38815172
8.
Virtual Molecular and Precision Medicine Clinic to Improve Access to Clinical Trials for Patients With Metastatic Breast Cancer: An Academic/Community Collaboration.
JCO Oncol Pract
; 20(1): 69-76, 2024 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-37922440
9.
Circulating Tumor DNA in Breast Cancer: Current and Future Applications.
Clin Breast Cancer
; 23(7): 687-692, 2023 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-37438196
10.
Molecular Residual Disease in Breast Cancer: Detection and Therapeutic Interception.
Clin Cancer Res
; 29(22): 4540-4548, 2023 11 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-37477704
11.
TRK inhibitor in a patient with metastatic triple-negative breast cancer and NTRK fusions identified via cell-free DNA analysis.
Ther Adv Med Oncol
; 15: 17588359231152844, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-36743521
12.
Cyclin-Dependent Kinase 4/6 Inhibitors Beyond Progression in Metastatic Breast Cancer: A Retrospective Real-World Biomarker Analysis.
JCO Precis Oncol
; 7: e2200531, 2023 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-37141549
13.
Genetic Alterations Detected by Circulating Tumor DNA in HER2-Low Metastatic Breast Cancer.
Clin Cancer Res
; 29(16): 3092-3100, 2023 08 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-37265453
14.
Antibody-Drug Conjugates in Breast Cancer: Spotlight on HER2.
Cancer J
; 28(6): 423-428, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-36383904
15.
Circulating tumour DNA characterisation of invasive lobular carcinoma in patients with metastatic breast cancer.
EBioMedicine
; 86: 104316, 2022 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-36332363
16.
Antibody drug conjugates for patients with breast cancer.
Curr Probl Cancer
; 45(5): 100795, 2021 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-34635342
17.
Rising Circulating Tumor DNA As a Molecular Biomarker of Early Disease Progression in Metastatic Breast Cancer.
JCO Precis Oncol
; 4: 1246-1262, 2020 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-35050782
18.
Blood-based monitoring identifies acquired and targetable driver HER2 mutations in endocrine-resistant metastatic breast cancer.
NPJ Precis Oncol
; 3: 18, 2019.
Artigo
em Inglês
| MEDLINE | ID: mdl-31341951
19.
Hotspot SF3B1 mutations induce metabolic reprogramming and vulnerability to serine deprivation.
J Clin Invest
; 129(11): 4708-4723, 2019 08 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-31393856
20.
Detection of Cancer DNA in Early Stage and Metastatic Breast Cancer Patients.
Methods Mol Biol
; 1768: 209-227, 2018.
Artigo
em Inglês
| MEDLINE | ID: mdl-29717446